IPO Boutique

Syndax Pharmaceuticals, Inc. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on Syndax Pharmaceuticals, Inc., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
Syndax Pharmaceuticals, Inc.SNDX -
NASDAQ
$14.00-$16.00 $12.00 $12.114.4 million3/3/2016
Morgan Stanley, Citigroup
Co-Manager(s):
JMP Securities, Oppenheimer & Co.
Health Care
Filing(s):

1st Filed 2014-03-27
Terms Added 2014-06-05
Amended Terms 2014-08-28
Filed 2016-01-04
Terms Added 2016-02-22



Syndax Pharmaceuticals, Inc. Quote & Chart - Click for current quote - SNDX

About Syndax Pharmaceuticals, Inc. (adapted from Syndax Pharmaceuticals, Inc. prospectus):
They are a late-stage biopharmaceutical company focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.

This description is adapted from Syndax SNDX prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as Syndax SNDX "SNDX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved